#

COPD

  • Compensation to be determined
  • 13 visits (enrollment open)
#

18+ Years

#
Male or Female
#
Smoker & Non-Smoker

Description

This is a phase III, multinational, multicenter, randomized, double-blind, 2-arm parallel group study. Comparing efficacy, safety and tolerability of the fixed dose triple combination of Beclomethasone Dipropionate/Fluticasone Furoate/Glycopyrronium Bromide 100/6/12.5µg with the fixed dose dual combination of Beclomethasone Dipropionate/Fluticasone Furoate 100/6µg. The study will last approximately 55 weeks for each subject.

Is this not what you are looking for?
Check out our other studies.

Related Studies

#

COPD

  • Compensation to be determined
  • 12 clinic visits
#
18+ Years

#
Male or Female
#
Smoker & Non-Smoker
#

Gout

  • Compensation to be determined
  • Clinical visits 17
#
Between 19+ Years

#
Male or Female
#
Smoker & Non-Smoker
#

Depression (ALTO)

  • Compensation to be determined
  • The total number of visits is 12 with 5 visits in clinic and 7 remote visits
#
Between 18 - 65 Years

#
Male or Female
#
Smoker & Non-Smoker
© 2024 Access Research Institute. All Rights Reserved